[China, Shanghai, December 20, 2021] SciClone Pharmaceuticals (Holdings) Limited. (the “Company” or “SciClone Pharmaceuticals”, together with its subsidiaries, the “Group”, stock code: 6600. HK) announced that it has established a strategic partnership with Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed", stock code: 300347.SZ/3347.HK). These two parties will work closely to accelerate the innovation of SciClone Pharmaceuticals’ clinical research and development, to meet the unmet medical needs of patients in the area of tumors, severe infections, and other diseases.
On December 17, Mr. Zhao Hong, President, and CEO of Sciclone Pharmaceuticals, and Dr. Ye Xiaoping, Chairman of Tigermed, signed a strategic cooperation agreement in SciClone’s Shanghai office. A number of senior managers from both companies attended and witnessed the signing ceremony.
With many years of good cooperation between the two parties, SciClone Pharmaceuticals and Tigermed will carry out a full range of in-depth cooperation in the field of clinical research and development of innovative drugs based on the principles of complementary advantages and sincere cooperation according to the agreement. It includes clinical trials and registration application, data management and statistical analysis, biological analysis/central laboratory, clinical trial research center coordination, medical papering/medical monitoring services, medical imaging, pharmacovigilance, third-party inspection and training, clinical cold chain logistics, etc. At the same time, a close communication and coordination mechanism will be established between the two parties, as well as regularly high-level joint meetings and major studies in the strategic cooperation.
Mr. Zhao Hong
President and CEO of SciClone Pharmaceuticals
Mr. Zhao Hong, President and CEO of SciClone Pharmaceuticals said: “Tigermed is a leading clinical research CRO company which is able to provide a full range of innovative drug clinical research solutions with its strong clinical research service capabilities and a global service network layout in the pharmaceutical industry. I'm glad that our two sides have successfully reached the strategic cooperation to jointly meet the health needs of patients. I believe that this strategic cooperation will help further strengthen SciClone Pharmaceuticals’ R&D capabilities, so that more innovative drugs can benefit Chinese and even global patients earlier, bringing vitality and hope to human lives."
Dr. Ye Xiaoping
Chairman of Tigermed
Dr. Ye Xiaoping, Chairman of Tigermed, said: “SciClone Pharmaceuticals takes patient health as its own responsibility, and it has built a product pipeline of innovative drug products with its distinctive and differentiated advantages, and also established excellent capabilities of product development and commercialization. SciClone Pharmaceuticals and Tigermed share the common goals of benefiting human health, and I’m very pleased that this strategic cooperation has been successfully achieved. Tigermed ’s end-to-end solution, which covers the entire life cycle of new drug research and development, will help SciClone Pharmaceuticals to further accelerate new drug R&D, launch more high-quality innovative products as quickly as possible to fill the unmet clinical needs and to benefit patients worldwide."
About SciClone Pharmaceuticals
SciClone Pharmaceuticals is a biopharmaceutical company with an integrated platform for product development and commercialization. SciClone Pharmaceuticals strategically focuses on some of the largest and fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. With its product development and commercialization strength, SciClone Pharmaceuticals has established a good track record in terms of balanced and high-quality products on the market in key therapeutic areas and in developing and commercializing portfolios of pipeline products with better potential.
For more information about SciClone Pharmaceuticals, please visit:
www.sciclone.com
Contacts :
For SciClone Pharmaceuticals
ir@sciclone.com
pr@sciclone.com